Cardiol Therapeutics: Funding, Investors & Team (Sep 2026)
Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol Therapeutics leverages their expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.
Cardiol Therapeutics has raised $50.2M across 1 funding round on record, the most recent a Post-IPO Equity of $50.2M announced in Nov 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cardiol Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2021.
Cardiol Therapeutics Funding Rounds
Cardiol Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Cardiol Therapeutics Funding Compared to Other Biotechnology Startups
Cardiol Therapeutics' latest round of $50.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cardiol Therapeutics in Biotechnology and Oakville
Companies Similar to Cardiol Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Cardiol Therapeutics Funding FAQs
What does Cardiol Therapeutics do?
Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol Therapeutics leverages their expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.
How much funding has Cardiol Therapeutics raised?
Cardiol Therapeutics has raised $50.2M across 1 round on record. The most recent is a Post-IPO Equity of $50.2M announced in Nov 2021.
When did Cardiol Therapeutics last raise funding?
Cardiol Therapeutics' most recent funding round on record is a Post-IPO Equity of $50.2M, announced in Nov 2021.
Who is the CEO of Cardiol Therapeutics?
David Elsley is listed as CEO at Cardiol Therapeutics.
Where is Cardiol Therapeutics headquartered?
Cardiol Therapeutics is based in Oakville, Ontario, Canada.
How many employees does Cardiol Therapeutics have?
Cardiol Therapeutics is in the 11-50 employee band.
How does Cardiol Therapeutics' funding compare to other Biotechnology startups?
Cardiol Therapeutics' latest round of $50.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Cardiol Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cardiol Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.